Isotechnika Pharma Announces Agreement With U.S. National Institutes of Health ... MarketWatch (press release) Pursuant to the agreement, NIAID-funded contractors will evaluate the Company's portfolio of non-immunosuppressive cyclosporine analogue molecules ("NICAMs") as anti-viral agents. Isotechnika's NICAM portfolio will be tested through NIAID's preclinical ... |
